Model RPIDD - Rapid Pathogen Identification and Detection Device Technology
RPIDD: Next-generation molecular-based diagnostics for unbiased' detection of any foreign pathogens (virus, bacteria, fungus, parasites) in infected patients using DNA/RNA; <24 hours turnaround time + cost effective, Blood sample and adaptable to others (including swab), Collaboration with technology from Nobel prize winner Sydney Brenner / A*Star Sg, Patented proprietary technology to prepare and enrich the pathogenic DNA/RNA and, deplete the background human host DNA simultaneously + AI analysis
CAPABILITIES
Based on internal tests, our technology can detect:
- A full range of DNA/RNA viruses, bacteria, fungi, parasites, including coronavirus such as COVID19
- Pathogen genes that cause antibiotic/antimicrobial resistance (e.g. MRSA)
- Previously unknown and novel mutated pathogens (e.g. new virus)
Based on internal tests, our technology can:
- REDUCE diagnosis time to 24 hours or less (vs avg. 3 5 days using blood culture)
- REDUCE cost of existing NGS-based diagnosis by more than 50%
- TARGET TO ACHIEVE analytical specificity >99.99% per pathogen + sensitivity >95%
- 'Personalized Medicine' approach to infections allowing clinicians to prescribe suitable and targeted treatments at an early stage of admission of the patient
Customer reviews
No reviews were found for Model RPIDD - Rapid Pathogen Identification and Detection Device Technology. Be the first to review!